Piperazine

Piperazine

SCHEMBL3229382

C1=CNCNC1.C1=CNNCC1.C1CNCCN1

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ESR1

The experimentally established mechanism targets of Piperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5592529 0.96
SCHEMBL6356002 0.82
Piperazine SCHEMBL3888557 0.82 HIF1A (0.33)
SCHEMBL2360350 0.78
SCHEMBL1829972 0.75
SCHEMBL27859696 0.74
SCHEMBL122361 0.74
SCHEMBL121600 0.74
Bromide SCHEMBL17434706 0.72
Hydrochloric Acid SCHEMBL6193526 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110059981-A9 New Pyridine Analogues V ASTRAZENECA AB (SE) 2011-03-10 US disclosed
US-20100137277-A1 PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS ASTRAZENECA AB (SE) 2010-06-03 US disclosed
US-20100069350-A1 New Pyridine Analogues III ASTRAZENECA AB (SE) 2010-03-18 US disclosed
WO-2010005384-A1 KETONE PYRIDINE ANALOGUES AND THEIR USE IN THE TREATMENT OF CARDIOVASCULAR DISORDERS ASTRAZENECA AB (SE) 2010-01-14 WO disclosed
WO-2010005385-A1 2-AMINO-6-ALKYL SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS P2Y12 INHIBITORS 308 ASTRAZENECA AB (SE) 2010-01-14 WO disclosed
US-20090318464-A1 New Pyridine Analogues V ASTRAZENECA AB (SE) 2009-12-24 US disclosed
US-20090312368-A1 Pyridine Analogues IV ASTRAZENECA AB (SE) 2009-12-17 US disclosed
US-20090227555-A2 Novel Pyridine Compounds ASTRAZENECA AB (SE) 2009-09-10 US disclosed
CN-101511815-A New pyridine analogues ASTRAZENECA AB (SE) 2009-08-19 CN disclosed
CN-101506193-A New pyridine analogues ASTRAZENECA AB (SE) 2009-08-12 CN disclosed
US-20080032992-A1 New Pyridine Analogues V ASTRAZENECA AB (SE) 2008-02-07 US disclosed
WO-2008004941-A1 NEW PYRIDINE ANALOGUES ASTRAZENECA AB (SE) 2008-01-10 WO disclosed
WO-2008004946-A1 NEW PYRIDINE ANALOGUES ASTRAZENECA AB (SE) 2008-01-10 WO disclosed
US-20080009523-A1 New Pyridine Analogues IV ASTRAZENECA AB (SE) 2008-01-10 US disclosed
WO-2008004942-A1 NEW PYRIDINE ANALOGUES ASTRAZENECA AB (SE) 2008-01-10 WO disclosed
WO-2008002247-A1 NEW PYRIDINE ANALOGUES ASTRAZENECA AB (SE) 2008-01-03 WO disclosed
US-20070244088-A1 New Pyridine Analogues II ASTRAZENECA AB (SE) 2007-10-18 US disclosed
EP-1836189-A1 NOVEL PYRIDINE COMPOUNDS AstraZeneca AB (SE) 2007-09-26 EP disclosed
WO-2007008140-A1 NEW PYRIDINE ANALOGUES ASTRAZENECA AB (SE) 2007-01-18 WO disclosed
WO-2006073361-A1 NOVEL PYRIDINE COMPOUNDS ASTRAZENECA AB (SE) 2006-07-13 WO disclosed